These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3895561)

  • 1. Induction of a sustained fibrinolytic response by BRL 26921 in vitro.
    Fears R; Green J; Smith RA; Walker P
    Thromb Res; 1985 May; 38(3):251-60. PubMed ID: 3895561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of the acylated streptokinase-plasminogen activator complex BRL 33 575 incubated with normal human plasma.
    Lämmle B; Noll G; Tran TH; Lohri A; Duckert F
    Thromb Haemost; 1984 Jul; 51(3):403-5. PubMed ID: 6548585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of acylated streptokinase-plasminogen complex and streptokinase in healthy volunteers.
    Prowse CV; Hornsey V; Ruckley CV; Boulton FE
    Thromb Haemost; 1982 Apr; 47(2):132-5. PubMed ID: 7048621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrin clot lysis by thrombolytic agents is impaired in newborns due to a low plasminogen concentration.
    Andrew M; Brooker L; Leaker M; Paes B; Weitz J
    Thromb Haemost; 1992 Sep; 68(3):325-30. PubMed ID: 1440499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a sustained fibrinolytic response to anisoylated plasminogen streptokinase activator complex in vitro.
    Fears R
    Drugs; 1987; 33 Suppl 3():83-7. PubMed ID: 3315617
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential effects of staphylokinase, streptokinase and tissue-type plasminogen activator on the lysis of retracted human plasma clots and fibrinolytic plasma parameters in vitro.
    Hauptmann J; Glusa E
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):579-83. PubMed ID: 7578902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M; Zenker M; Klinge J; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 11. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards.
    Brommer EJ
    Thromb Res; 1984 Apr; 34(2):109-15. PubMed ID: 6539513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of fibrinolysis.
    Haire WD
    Chest; 1992 Apr; 101(4 Suppl):91S-97S. PubMed ID: 1555484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex.
    Ferres H
    Drugs; 1987; 33 Suppl 3():33-50. PubMed ID: 3315613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) enhances plasma clot lysis in vitro.
    Mao SJ; Tucci MA
    FEBS Lett; 1990 Jul; 267(1):131-4. PubMed ID: 2142106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of various combinations of plasminogen and streptokinase on fibrinolysis.
    Gaffney PJ; Joe F; Rowe EA; Whitaker AN
    Haemostasis; 1981; 10(6):304-14. PubMed ID: 7327440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinolysis in vitro by acylated derivatives of a plasmin-streptokinase activator complex].
    Aĭsina RB; Popova GIu; Eremeev NL; Kazanskaia NF
    Ukr Biokhim Zh (1978); 1991; 63(2):27-31. PubMed ID: 1882459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase-plasminogen complex (BRL 26921).
    Matsuo O; Collen D; Verstraete M
    Thromb Res; 1981 Nov; 24(4):347-58. PubMed ID: 7038976
    [No Abstract]   [Full Text] [Related]  

  • 18. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Binding of an acylated plasminogen activator-streptokinase complex with fibrin and the fibrinolytic response in vitro].
    Aĭsina RB; Zhitkova IuV; Varfolomeev SD
    Vopr Med Khim; 1994; 40(3):31-5. PubMed ID: 8079435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.